Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

Abstract

Novartis and Pfizer.

Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma

“…ChRCC is relatively indolent despite its usual presentation as larger tumors (10), yet ~5%-10% of patients eventually develop metastases (11,12). Thus far, there are no genomic biomarkers that predict metastatic progression, and no standard of care for metastatic chRCC (M-chRCC) (13)(14)(15)(16)(17).…”

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017

“…68 The ASPEN trial demonstrated sunitinib was superior to everolimus for PFS. 69 Thus, sunitinib is the preferred first-line treatment for nonclear-cell RCC.…”

Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis

“…The RAPTOR trial evaluated everolimus as monotherapy in pRCC and found that it was beneficial, with a median OS of 21 months and a similar difference between type 1 (median OS 28 mo) and type 2 (median OS 20 mo) (19). ASPEN (20) and ESPN (21) are two recently published phase 2 trials comparing sunitinib and everolimus as first line therapy in patients with metastatic non-clear cell RCC. Of note, there were significant differences in the trial populationsthe ESPN trial included sarcomatoid clear cell RCC and 39.7% pRCC whereas ASPEN did not allow any clear cell RCC and 66% of subjects had pRCC.…”